The molecular events and transcriptional plasticity driving brain metastasis in clinically
relevant breast tumor subtypes has not been determined. Here we comprehensively dissect …

Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or
acquired resistance to second-generation androgen-targeting therapies and minimal …

Cell-free DNA (cfDNA) has the potential to inform tumor subtype classification and help
guide clinical precision oncology. Here we develop Griffin, a framework for profiling …

Translocation renal cell carcinoma (tRCC) is a poorly characterized subtype of kidney
cancer driven by MiT/TFE gene fusions. Here, we define the landmarks of tRCC through an …

Drug combination therapies for cancer treatment show high efficacy but often induce severe
side effects, resulting in dose or cycle number reduction. We investigated the impact of …

We report an approach for cancer phenotyping based on targeted sequencing of cell-free
DNA (cfDNA) for small cell lung cancer (SCLC). In SCLC, differential activation of …

Xp11 translocation renal cell carcinoma (tRCC) is a rare, female-predominant cancer driven
by a fusion between the transcription factor binding to IGHM enhancer 3 (TFE3) gene on …

High-risk localized prostate cancer (HRLPC) is associated with a substantial risk of
recurrence and disease mortality. Recent clinical trials have shown that intensifying anti …

Saliby et al. show that a machine learning approach can accurately classify clear cell renal
cell carcinoma (RCC) into distinct molecular subtypes using transcriptomic data. When …

Mullerian clear cell carcinoma (CCC) is often aggressive and chemoresistant. The
prognostic significance of molecular subclassification of endometrioid carcinomas is well …